Nektar Therapeutics provided revenue guidance for the full year 2022. The company announced that GAAP revenue is expected to be between $185 million and $195 million in 2022, including the $100 million of BMS collaboration milestones related to BEMPEG regulatory filings.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.685 USD | -3.71% | -5.83% | +200.00% |
05-09 | Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q1 Revenue $21.6M, vs. Street Est of $15.3M | MT |
05-09 | Transcript : Nektar Therapeutics, Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+200.00% | 321M | |
+37.89% | 723B | |
+34.28% | 595B | |
-4.44% | 369B | |
+20.07% | 332B | |
+2.69% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.07% | 168B |
- Stock Market
- Equities
- NKTR Stock
- News Nektar Therapeutics
- Nektar Therapeutics Provides Revenue Guidance for the Full Year 2022